We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




On-Site DNA Analysis Could Soon Become Available

By LabMedica International staff writers
Posted on 30 Dec 2008
A European Union- (EU)-funded project is in the process of developing a novel microsystem that could be used in a portable diagnostic device to analyze simultaneously and automatically various DNA samples with high precision.

The Smart-Biomems project (Rome, Italy) aims at developing a novel micro-total analysis system with fully integrated functionalities for diagnostic genotyping of point mutations and single nucleotide polymorphisms (SNPs). More...
The basis of the system relies on a MEMS (micro-electro mechanical system) platform. Since cancer is a particularly important potential field, the first prototype device is being developed for genotyping of clinically important mutations and common SNPs of the tumor protein 53 (TP53) gene, using tag-array minisequencing. Active flow control (AFC) components are specifically designed and integrated for appropriate control of heating and flow inside of a polymer-based microfluidic chip.

During testing, a liquidized DNA sample is inserted into the device, and a liquid plug fluid sample of a specific volume is then transferred into the microchip by a pressure control unit, which moves it through a network of micro-channels and chambers where the reactions take place. The entire process is automatic, eliminating the possibility of human error or contamination of the sample. The device is connected to a standard personal computer (PC) equipped with a camera capable of acquiring fluorescent images generated by the device. Proprietary software, specially developed by the EU project, analyzes the images and displays the test results on the computer monitor.

"We will use a known sample--where we know the mutations--and test the capability of the system to identify these mutations. We will then compare the results of our tests with results from a conventional testing procedure to check on the accuracy of the results and the time our microsystem takes to complete the analysis,” said project coordinator Mr. Gianluca Vezzani. "Should the prototype work, which we are sure it will do, we think it would take two to three years after the end of the project to see a commercial device, and these could be available by 2012. Right from the start, we have tried to design a cost-effective system.”

The TP53 protein acts as a tumor suppressor, regulating cell division. It is located in the cell nucleus, where it binds directly to DNA. When the DNA in a cell becomes damaged by agents such as toxic chemicals, radiation, or ultraviolet (UV) rays from sunlight, this protein plays a critical role in determining whether the DNA will be repaired or the damaged cell will undergo apoptosis. If the DNA can be repaired, tumor protein p53 activates other genes to fix the damage. If the DNA cannot be repaired, this protein prevents the cell from dividing and signals it to self-destruct. This process prevents cells with mutated or damaged DNA from dividing, which helps prevent the development of tumors.

Related Links:
Smart-Biomems Project


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.